SSRX » Topics » Capital Expenditures

This excerpt taken from the SSRX 20-F filed Apr 21, 2009.

Capital Expenditures

The following sets forth our total capital expenditures for the periods indicated.

 

     (RMB in
thousands)
   (US$ in
thousands)

2006

   2,671    N/A

2007

   17,314    N/A

2008

   36,777    5,391

Historically, most of our capital expenditures were incurred for purchases of production and office equipment, research laboratory, upgrade for our plant and office renovation.

In the year ended December 31, 2008, our capital expenditure of RMB36.8 million (US$5.4 million) related primarily to upgrading of existing facilities, construction of new manufacturing facilities, and purchases of office equipment and other fixed assets.

In the year ended December 31, 2007, our capital expenditures of RMB17.3 million related primarily to upgrading of existing facilities, office renovation, and purchases of office equipment and other fixed assets.

In the year ended December 31, 2006, our capital expenditures of RMB2.7 million related primarily to purchases of office and production equipment for our TPIAO and EPIAO products and, to a lesser extent, purchase of automobiles.

Our future capital requirements may include, but are not limited to, upgrading our existing facilities for our research and development and production to meet EMEA standards and to build new facilities. Although we are not obligated to meet any absolute minimum dollar spending requirements, our future capital requirements will depend on many factors, including the scope and progress made in building our new manufacturing facilities in the next two years. The major component of our planned capital expenditures for 2009 is construction of the new manufacturing facilities.

We expect to fund our capital expenditure needs with a combination of cash generated from operating activities and our existing cash, cash equivalents and time deposits without much need for debt financing. Therefore, we believe that the anticipated higher depreciation charges related to our ongoing and planned facility expansion could be offset to a certain extent by the expected reduction in interest costs.

This excerpt taken from the SSRX 20-F filed Jun 27, 2008.

Capital Expenditures

The following sets forth our total capital expenditures for the periods indicated.

 

     (RMB in
thousands)
   (US$ in
thousands)

2005

   9,151    1,254

2006

   2,671    366

2007

   17,314    2,373

 

71


Historically, most of our capital expenditures were incurred for purchases of production and office equipment, research laboratory, upgrade for our plant and office renovation. In the year ended December 31, 2007, our capital expenditure of RMB17.3 million (US$2.4 million) related primarily to upgrading of existing facilities, construction of new manufacturing facilities, office renovation, and purchases of office equipment and other fixed assets.

In the year ended December 31, 2006, our capital expenditures of RMB2.7 million related primarily to purchases of office and production equipment for our TPIAO and EPIAO products and, to a lesser extent, purchase of automobiles.

Capital expenditures in 2005 totaled RMB9.2 million, approximately half of which was related to equipment acquired for the production of TPIAO, with the remaining attributable to general office equipment, final payment and renovation cost for our Beijing office and purchases of automobiles.

Our future capital requirements include, but are not limited to, upgrading our existing facilities for our research and development and production to meet EMEA standards and to build new facilities. Although we are not obligated to meet any absolute minimum dollar spending requirements, our future capital requirements will depend on many factors, including the scope and progress made in building our new manufacturing facilities in the next two years. The major component of our planned capital expenditures for 2008 is construction of the new manufacturing facilities.

We expect to fund our capital expenditure needs with a combination of cash generated from operating activities and proceeds from our initial public offering in February 2007 without much need for debt financing. Therefore, we believe that the anticipated higher depreciation charges related to our ongoing and planned facility expansion could be offset to a certain extent by the expected reduction in interest costs.

This excerpt taken from the SSRX 20-F filed Jun 29, 2007.

Capital Expenditures

The following sets forth our actual and planned total capital expenditure requirements for the periods indicated.

 

     (RMB in
thousands)
   (US$ in
thousands)

2004

   901    115

2005

   9,151    1,173

2006

   2,671    342

2007 (Planned)

   33,300    4,267

2008 (Planned)

   43,330    5,548

Historically, most of our capital expenditures were incurred for purchases of production and office equipment, research laboratory, upgrade for our plant and office renovation. In the year ended December 31, 2006, our capital expenditures of RMB2.7 million (US$0.3 million) related primarily to purchases of office and production equipment for our TPIAO and EPIAO products and, to a lesser extent, purchase of automobiles.

The level of our capital expenditure was substantially higher in 2005, as compared to 2004. Capital expenditures in 2005 totaled RMB9.2 million, compared to RMB0.9 million in 2004. Approximately half of the increase in 2005 was related to equipment acquired for the production of TPIAO, with the remaining attributable to general office equipment, final payment and renovation cost for our Beijing office and purchases of automobiles.

Our future capital requirements include, but are not limited to, upgrading our existing facilities for our research and development and production to meet EMEA standards and to build new facilities. Although we are not obligated to meet any absolute minimum dollar spending requirements, our future capital requirements will depend on many factors, including the scope and progress made in building out our new plant in the next two years. The major components of our planned capital expenditures for 2007 include further procurement of production equipment such as a new power generator and quality control machineries, in addition to further upgrading our plant facilities to comply with EMEA requirements.

We expect to fund our capital expenditure needs with a combination of cash generated from operating activities and proceeds from our initial public offering in February 2007 without much need for debt financing. Therefore, we believe that the anticipated higher depreciation charges could be offset to a certain extent by the expected reduction in interest costs.

"Capital Expenditures" elsewhere:

Tongjitang Chinese Medicines Company (TCM)
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki